NeuroPace’s RNS System study will be presented at the AAN 2025 Annual Meeting, focusing on focal epilepsy outcomes.
Quiver AI Summary
NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be presented at the American Academy of Neurology's 2025 Annual Meeting in San Diego from April 5th to 9th. The oral presentation titled "Multicenter Post-approval Study of the RNS System in Focal Epilepsy" will be delivered by Dr. Dawn Eliashiv on April 7th at 5:06 PM PT. NeuroPace's RNS System is a unique, brain-responsive platform designed to provide real-time, personalized treatment for patients with drug-resistant epilepsy, aiming to enhance patient outcomes and offer solutions for other brain disorders.
Potential Positives
- An abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at a prestigious annual meeting, enhancing the company’s visibility and credibility within the medical community.
- The presentation highlights the RNS System's positive impact on patients with drug-resistant epilepsy, emphasizing the company’s commitment to improving patient outcomes.
- This opportunity for presentation at the American Academy of Neurology Annual Meeting positions NeuroPace as a leader in innovation in the epilepsy treatment space, potentially attracting interest from healthcare professionals and investors.
Potential Negatives
- None
FAQ
What is the RNS System by NeuroPace?
The RNS System is a brain-responsive platform that delivers personalized, real-time treatment for people living with drug-resistant epilepsy.
When will the RNS System study be presented at AAN 2025?
The study will be presented on April 7th, 2025, at 5:06 PM PT during the AAN Annual Meeting.
Who is presenting the RNS System study at AAN 2025?
Dr. Dawn Eliashiv, a Professor of Neurology and Co-Director of the UCLA Seizure Disorders Center, will present the study.
What is the focus of NeuroPace, Inc.?
NeuroPace focuses on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures.
Where is NeuroPace, Inc. located?
NeuroPace, Inc. is based in Mountain View, California.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NPCE Insider Trading Activity
$NPCE insiders have traded $NPCE stock on the open market 32 times in the past 6 months. Of those trades, 0 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $NPCE stock by insiders over the last 6 months:
- LTD. KCK has made 0 purchases and 29 sales selling 322,928 shares for an estimated $1,878,231.
- MARTHA MORRELL (CHIEF MEDICAL OFFICER) has made 0 purchases and 3 sales selling 3,500 shares for an estimated $52,532.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NPCE Hedge Fund Activity
We have seen 21 institutional investors add shares of $NPCE stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 480,000 shares (+inf%) to their portfolio in Q3 2024, for an estimated $3,345,600
- KCK LTD. removed 350,266 shares (-6.2%) from their portfolio in Q4 2024, for an estimated $3,919,476
- DEUTSCHE BANK AG\ removed 241,429 shares (-36.9%) from their portfolio in Q3 2024, for an estimated $1,682,760
- NORTHERN TRUST CORP added 117,647 shares (+279.0%) to their portfolio in Q3 2024, for an estimated $819,999
- ACADIAN ASSET MANAGEMENT LLC removed 65,352 shares (-94.8%) from their portfolio in Q3 2024, for an estimated $455,503
- MILLENNIUM MANAGEMENT LLC added 53,956 shares (+7.9%) to their portfolio in Q3 2024, for an estimated $376,073
- MAN GROUP PLC removed 38,470 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $268,135
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5 th – 9 th in San Diego.
Presentation Details:
|
|
Title: | Multicenter Post-approval Study of the RNS System in Focal Epilepsy |
Presenter: | Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of the UCLA Seizure Disorders Center |
Session: | S20: Epilepsy Clinical Outcomes and Prognostication |
Presentation number: | 009 |
Date and Time: | Monday, April 7 th , at 5:06 PM PT |
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
[email protected]